tradingkey.logo

Celcuity Announces Positive Topline Results From PIK3CA Wild-Type Cohort Of Phase 3 VIKTORIA-1 Clinical Trial

ReutersJul 28, 2025 10:15 AM

- Celcuity Inc CELC.O:

  • CELCUITY: GEDATOLISIB + FULVESTRANT REDUCED RISK OF PROGRESSION OR DEATH BY 67% VERSUS. FULVESTRANT

  • CELCUITY: TOPLINE DATA FOR VIKTORIA-1 PIK3CA MUTATION COHORT IS EXPECTED BY END OF 2025

  • CELCUITY: EXPECTS TO SUBMIT NEW DRUG APPLICATION FOR GEDATOLISIB TO U.S. FDA IN Q4 2025

  • CELCUITY: CLINICALLY MEANINGFUL IMPROVEMENT IN BOTH PFS PRIMARY ENDPOINTS FROM PIK3CA WILD-TYPE COHORT OF PHASE 3 VIKTORIA-1 TRIAL

  • CELCUITY: GEDATOLISIB + PALBOCICLIB + FULVESTRANT REDUCED RISK OF DISEASE PROGRESSION OR DEATH BY 76% VERSUS. FULVESTRANT

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI